Assistant Professor, Medicine, Brigham and Women's Hospital, Harvard Medical School

Oncology

John Koreth works in the field of Oncology. He went to medical school at Maulana Azad Medical College. Dr. John Koreth is also published. He has 36 publications published. The lastest publication: "Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease.' He accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• Circulating T follicular helper cells with increased function during Chronic graft-versus-host-disease.
• A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A P...
• Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions.
• Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for Acute myeloid leukaemia and myelodysplastic syndromes.
• Increasing incidence of Chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
• Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome.
• A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease.
• Somatic mutations predict poor outcome in patients with Myelodysplastic syndrome after hematopoietic stem-cell transplantation.
• Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival.
• Increased T follicular helper cells and germinal center B cells are required for Chronic GVHD (cGVHD) and bronchiolitis obliterans.
• White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.
• Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease.
• Effect of post remission therapy prior to reduced intensity conditioning allogeneic transplantation for Acute myeloid leukemia in first complete remission.
• Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.
• Tregs, HSCT, and Acute GVHD: up close and personal.
• Autologous CLL cell vaccination early after transplant induces Leukemia-specific T cells.
• Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
• Rituximab prophylaxis prevents corticosteroid-requiring Chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
• Paneth cells in gut GVHD: a Panglossian perspective.
• Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.
• Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo Myelodysplastic syndromes: an international co...
• Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia.
• Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with Chronic graft-versus-host disease.
• Optimal positioning of hematopoietic stem cell transplantation for older patients with Myelodysplastic syndromes.
• A Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease.
• Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic Leukemia: prognostic model to predict outcome.
• Pre-transplantation iron chelation in patients with MDS or Acute leukemia and iron overload undergoing myeloablative allo-SCT.
• KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation.
• Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated Acute limbic encephalitis: a cohort analysis.
• Bortezomib-based Graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
• A Disease risk index for patients undergoing allogeneic stem cell transplantation.
• Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation.
• Does iron overload really matter in stem cell transplantation?
• Altered B-cell homeostasis and excess BAFF in human Chronic graft-versus-host disease.
• Sirolimus is associated with veno-occlusive Disease of the liver after myeloablative allogeneic stem cell transplantation.

Schools

---

• Maulana Azad Medical College Delhi University

• Brigham and Women39s Hospital

• Dana Farber Cancer Institute

Procedures Preformed

---

• HPC Transplantation (Stem Cell Transplant)
• Plasmapheresis

Conditions Treated

---

• Acute Leukemia
• Anemia
• Breast Cancer
• Carcinoma in Situ
• View All

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

• Choice Plus POS II
• Blue Card PPO
• BlueConnect HMO
• Blue with Managed Care Behavioral Health HMO
• Preferred Blue PPO
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• Open Access Plus
• Commercial Insurance Company
• Fallon Community Health Plan
• First Health (Coventry Health Care) PPO
• Medicare Advantage PFFS
• Choice Care PPO
• Medicare MCR
• MultiPlan PPO
• PHCS Network PPO
• Neighborhood Health Plan
• Tufts Health Plans
• Tufts PPO
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO
• United Healthcare

Education

---

• Brigham and Women's Hospital
• Maulana Azad Medical College

Hospital

---

• Brigham and Women's Hospital
• Massachusetts General Hospital
• Dana-Farber Cancer Institute

Drug Facts

---

NPI NUMBER		1396706503
NPPES Provider LastName		KORETH
NPPES Provider FirstName		JOHN
NPPES Provider ZIPCode		021156013
NPPES Provider State		MA
Specialty Description		Hematology/Oncology
Total Claim Count		187.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1396706503
Last Name Of The Provider	KORETH
First Name Of The Provider	JOHN
View All

Similar Doctors

---

	Dr. Rushdia Z. Yusuf, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniel A. Haber, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Bruce A. Chabner, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Judy Lieberman, MD This Doctor is OpenDoctor Recommended.
	Dr. Xiuning Le, MD
	Dr. Andrew J. Aguirre, MD This Doctor is OpenDoctor Recommended.
	Dr. Nishan Tchekmedyian, MD
	Dr. Bimalangshu R. Dey, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Jonathan E. Rosenberg, MD This Doctor is OpenDoctor Recommended.
	Dr. Marian H. Harris, MD This Doctor is OpenDoctor Recommended.
	Dr. Anna F. Farago, MD This Doctor is OpenDoctor Recommended.
	Dr. Ruben D. Carrasco, MD This Doctor is OpenDoctor Recommended.
	Dr. William G. Kaelin Jr., MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Adam B. Lerner, MD This Doctor is OpenDoctor Recommended.
	Dr. Matthew B. Yurgelun, MD This Doctor is OpenDoctor Recommended.
	Dr. M S. Donnelly, MD This Doctor is OpenDoctor Recommended.
	Dr. Pankaj Bhargava, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael B. Atkins, MD This Doctor is OpenDoctor Recommended.
	Dr. Amy C. Bessnow, MD This Doctor is OpenDoctor Recommended.
	Dr. David B. Smith, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael J. Birrer, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Sarah M. Scott, MD
	Dr. Aric D. Parnes, MD This Doctor is OpenDoctor Recommended.
	Dr. Amir T. Fathi, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Michael R. Cassidy, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog